Topic: infectious disease
With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.
A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results.
If the German contract manufacturer delivers all projects over the 10-year course, it could receive up to $80 million.
Sanofi's beleaguered dengue vaccine is expected to win European approval in December following a committee's vote in favor of the shot this week.
GSK touted data for what could be a promising vaccine against tuberculosis, a leading cause of death worldwide.
Zika vaccine research continues in the absence of a large-scale outbreak, but a shortage of cases is making it hard to test for efficacy.
China has withheld shipments of the H7N9 strain to the U.S. for research, according to The New York Times.
CDC officials have been pushing HPV vaccination, and in 2017—just as in the previous four years—those efforts yielded only a slight increase.
Profectus’ Lassa candidate is based on its VesiculoVax vaccine delivery platform, which uses vesicular stomatitis virus as vector.
Initial lab work suggests that the Ebola Zaire strain—the one targeted by Merck's rVSV-ZEBOV—is likely the cause of this outbreak.